Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)

J. Nam, E. Villeneuve, E.M.A. Hensor, P.G. Conaghan, Helen Keen, M.H. Buch, A.K.S. Gough, M.J. Green, P.S. Helliwell, A.M. Keenan, A.W. Morgan, M.A. Quinn, R.J. Reece, D.M.F.M. Van Der Heijde, R.J. Wakefield, P.D. Emery

    Research output: Contribution to journalArticlepeer-review

    108 Citations (Scopus)

    Abstract

    Objectives In disease modifying antirheumatic drug (DMARD)-naive early rheumatoid arthritis (RA), to compare the efficacy of methotrexate (MTX) and infliximab (IFX) with MTX and intravenous corticosteroid for remission induction. Methods In a 78-week multicentre randomised controlled trial, double-blinded to week 26, 112 treatment-naive RA patients (1987 American College of Rheumatology classification criteria) with disease activity score 44 (DAS44)>2.4 were randomised to MTX + IFX or MTX + single dose intravenous methylprednisolone 250 mg. A treat-to-target approach was used with treatment escalation if DAS44>2.4. In the IFX group, IFX was discontinued for sustained remission (DAS44
    Original languageEnglish
    Pages (from-to)75-85
    JournalAnnals of the Rheumatic Diseases
    Volume73
    Issue number1
    DOIs
    Publication statusPublished - 2014

    Fingerprint

    Dive into the research topics of 'Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)'. Together they form a unique fingerprint.

    Cite this